First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b
Primary Peritoneal Cancer
18 Years and older, Male and Female
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536
(upifitamab rilsodotin) administered as an intravenous infusion once every four weeks.
Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients
with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma
subtype) are being enrolled in the expansion segment of this study. Patients with
platinum-resistant, high-grade serous ovarian cancer are being enrolled in the UPLIFT segment
of this study. In addition to safety assessments, the pharmacokinetics of the drug will be
assessed along with ADC activity. A QTc sub-study has been added for the UPLIFT cohort for a
sub-set of sites.
This is a multi-center study of XMT-1536 (upifitamab rilsodotin) in patients with tumors
likely to express NaPi2b, focusing on patients with platinum-resistant ovarian cancer and
non-small cell lung cancer, adenocarcinoma subtype. XMT-1536 (upifitamab rilsodotin) will be
administered as an intravenous infusion once every four weeks. The study consists of three
segments: dose escalation (DES), dose expansion (EXP), and the pivotal cohort (UPLIFT). The
DES segment studied small groups of patients who received increased doses. A Safety Review
Committee was established to review the data from each dose level before moving to the next
higher dose. The dose escalation cohort has ended and is no longer enrolling patients.
Enrollment into the EXP segment consists of 2 parallel cohorts of patients to confirm the
dose that has been identified in DES and estimate the objective response rate in each patient
population. The EXP cohort is no longer enrolling patients. Enrollment into the pivotal
cohort (UPLIFT) includes patients with platinum-resistant ovarian cancer. All adverse events
will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria
version (CTCAE v5.0). Throughout the study, pharmacokinetics will be measured using
proprietary assays developed by Mersana. Anti-cancer activity will be measured via RECIST.
- General Inclusion Criteria (for Dose Escalation, Expansion, and UPLIFT):
- ECOG performance status 0 or 1
- Measurable disease as per RECIST, version 1.1
- Resolution of all acute toxic effects of prior therapy or surgical procedures to
=Grade 1 (except alopecia, stable immune-related toxicity such as hypothyroidism on
hormone replacement, adrenal insufficiency on =10 mg daily prednisone [or equivalent],
chronic Grade 2 peripheral sensory neuropathy after prior taxane therapy).
- Cardiac left ventricular ejection fraction (LVEF) =50% or = the institution's lower
limit of normal by either Echo or MUGA scan
- Adequate organ function as defined by the following criteria:
1. Absolute neutrophil count (ANC) =1500 cells/mm3
2. Platelet count =100,000/mm3
3. Hemoglobin =9 g/dL
4. In patients not on anticoagulation therapy: INR, activated partial thromboplastin
time (aPTT), and prothrombin time (PT) all within 1.2 times the institution's
upper limit of normal (ULN). Patients on anticoagulation therapy are allowed if
their relevant laboratory values are within the therapeutic window.
5. Estimated glomerular filtration rate (GFR) =45 mL/min
6. Total bilirubin =ULN
7. g. Patients with asymptomatic elevations in unconjugated bilirubin due to Gilbert
syndrome or stable chronic hemolytic anemia (e.g., hereditary spherocytosis,
sickle cell disease, thalassemia intermedia) may be eligible after discussion
with the Sponsor Medical Monitor.
- Aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT)
=1.5 times the institutional ULN.
- Albumin =3.0 g/dL
- Able to provide informed consent.
General Exclusion Criteria (for Dose Escalation, Expansion, and UPLIFT) :
- Major surgery within 28 days of starting study treatment, systemic anti-cancer therapy
within the lesser of 28 days or 5 half-lives of the prior therapy before starting
study treatment, or recent radiation therapy with unresolved toxicity or within a time
window of potential toxicity.
- Patients with untreated CNS metastases (including new and progressive brain
metastases), history of leptomeningeal metastasis or carcinomatous meningitis.
- Current known active infection with HIV, hepatitis B virus, or hepatitis C virus.
- Prior history of liver disease such as liver cirrhosis, hepatic fibrosis
- Current severe, uncontrolled systemic disease (e.g., clinically significant
cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could
interfere with per-protocol evaluations.
- Current use of either constant or intermittent supplementary oxygen therapy.
- History of suspected pneumonitis or interstitial lung disease.
- Pregnant or nursing women.
- History of other malignancy within the last 2 years, except for appropriately treated
carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with
a similar expected curative outcome.
- Active corneal disease, or history of corneal disease within 12 months prior to
- Use of strong CYP450 inhibitors
- Oxygen saturation on room air <93%
Ovarian Cancer Inclusion Criteria for UPLIFT:
- Histological diagnosis of high grade serous ovarian cancer, which includes fallopian
tube, or primary peritoneal cancer, that is metastatic or recurrent.
- Platinum-resistant disease
1. Patients who have only had 1 line of platinum-based therapy must have received at
least 4 cycles of platinum, must have had a response [complete response/remission
(CR) or partial response/remission (PR)], and then progressed between 3 months
and = 6 months after the date of the last dose of platinum
2. Patients who have received 2 to 4 lines of prior therapy must have received at
least 4 cycles of platinum and then progressed within 6 months after the date of
the last dose of platinum
- One to 4 prior lines of systemic therapy for ovarian cancer
a. Prior treatment with bevacizumab is required for patients with 1 to 2 prior lines
- Patients must be willing to provide an archival tumor tissue block or slides or if not
available, undergo procedure to obtain a new tumor biopsy using a low-risk, medically
Ovarian Cancer Exclusion Criteria for UPLIFT:
- Low-grade, clear cell, endometrioid, mucinous, carcinosarcoma, germ-cell, mixed
histology, or stromal tumors
- Prior treatment with mirvetuximab soravtansine or another ADC containing an
- Primary platinum-resistant disease, defined by a lack of response or by progression
within 3 months after completing front-line, platinum-containing therapy.
- Participation in DES or EXP segments of this study
Ovarian Cancer Inclusion Criteria for QTc sub-study:
Note: patients must meet all UPLIFT cohort inclusion criteria in order to participate in
the QTc sub-study
• Study patient has agreed to remain in the clinic for the additional QTc related study
activities on the Day 1 of Cycle 1 and Cycle 3.
Ovarian Cancer Exclusion Criteria for QTc sub-study:
- Use of strong CYP3A4 inducers.
- Uncontrolled cardiac arrhythmias, for example, atrial fibrillation with a ventricular
response at rest > 100 beats per minute. left bundle branch block (LBBB)
- Known abnormality of any cardiac valve (either stenosis or regurgitation) that is
greater than moderate in severity.
- Subjects not in sinus rhythm at screening with HR >45- <100
- Any ECG abnormality that can interfere with the measurement of the QT interval
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials